These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 1713218

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ, Lee BW, Kim JY, Jung JH, Min YK, Lee MS, Lee MK, Kim KW, Chung JH.
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Thyrotropin-releasing hormone testing during antithyroid drug treatment of Graves' disease as an indicator of remission.
    Dahlberg PA, Karlsson FA, Jansson R, Wide L.
    J Clin Endocrinol Metab; 1985 Dec; 61(6):1100-4. PubMed ID: 2414311
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Thyroid function and histology in forty-five patients with hyperthyroid Graves' disease in clinical remission more than ten years after thionamide drug treatment.
    Hirota Y, Tamai H, Hayashi Y, Matsubayashi S, Matsuzuka F, Kuma K, Kumagai LF, Nagataki S.
    J Clin Endocrinol Metab; 1986 Jan; 62(1):165-9. PubMed ID: 2415549
    [Abstract] [Full Text] [Related]

  • 10. Serum Thyroid Hormone Balance in Levothyroxine Monotherapy-Treated Patients with Atrophic Thyroid After Radioiodine Treatment for Graves' Disease.
    Ito M, Kawasaki M, Danno H, Kohsaka K, Nakamura T, Hisakado M, Yoshioka W, Kasahara T, Kudo T, Nishihara E, Fukata S, Nishikawa M, Nakamura H, Miyauchi A.
    Thyroid; 2019 Oct; 29(10):1364-1370. PubMed ID: 31411123
    [Abstract] [Full Text] [Related]

  • 11. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
    Brokken LJ, Wiersinga WM, Prummel MF.
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
    [Abstract] [Full Text] [Related]

  • 12. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
    Romaldini JH, Bromberg N, Werner RS, Tanaka LM, Rodrigues HF, Werner MC, Farah CS, Reis LC.
    J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
    [Abstract] [Full Text] [Related]

  • 13. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease.
    Chen JJ, Ladenson PW.
    J Clin Endocrinol Metab; 1986 Jul; 63(1):102-6. PubMed ID: 2423547
    [Abstract] [Full Text] [Related]

  • 14. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease.
    Burch HB, Solomon BL, Cooper DS, Ferguson P, Walpert N, Howard R.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3016-21. PubMed ID: 11443161
    [Abstract] [Full Text] [Related]

  • 15. Clinical experience with sensitive thyrotropin measurements: diagnostic and therapeutic implications.
    Bayer MF, Kriss JP, McDougall IR.
    J Nucl Med; 1985 Nov; 26(11):1248-56. PubMed ID: 3840528
    [Abstract] [Full Text] [Related]

  • 16. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M, Koizumi Y, Aizawa T, Yamada T, Takahashi Y, Watanabe T, Kamoi K.
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [Abstract] [Full Text] [Related]

  • 17. Thyroid vascularization by color doppler ultrasonography in Graves' disease. Changes related to different phases and to the long-term outcome of the disease.
    Baldini M, Castagnone D, Rivolta R, Meroni L, Pappalettera M, Cantalamessa L.
    Thyroid; 1997 Dec; 7(6):823-8. PubMed ID: 9459623
    [Abstract] [Full Text] [Related]

  • 18. Triiodothyronine-predominant Graves' disease in childhood: detection and therapeutic implications.
    Harvengt J, Boizeau P, Chevenne D, Zenaty D, Paulsen A, Simon D, Guilmin Crepon S, Alberti C, Carel JC, Léger J.
    Eur J Endocrinol; 2015 Jun; 172(6):715-23. PubMed ID: 25766047
    [Abstract] [Full Text] [Related]

  • 19. Low response of the thyroid gland to endogenous thyrotropin increased by thyrotropin-releasing hormone in patients with euthyroid Graves' disease.
    Kashiwai T, Tada H, Watanabe Y, Shimaoka Y, Yagoro A, Hidaka Y, Fujikado T, Amino N.
    Thyroid; 1998 Oct; 8(10):881-5. PubMed ID: 9827654
    [Abstract] [Full Text] [Related]

  • 20. Serum thyrotropin and prolactin in the syndrome of generalized resistance to thyroid hormone: responses to thyrotropin-releasing hormone stimulation and short term triiodothyronine suppression.
    Sarne DH, Sobieszczyk S, Ain KB, Refetoff S.
    J Clin Endocrinol Metab; 1990 May; 70(5):1305-11. PubMed ID: 2110573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.